Case Reports in Oncology (Sep 2023)

Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

  • Yujing J. Heng,
  • Kevin J. Zhang,
  • Monica G. Valero,
  • Gabrielle M. Baker,
  • Valerie J. Fein-Zachary,
  • Michael S. Irwig,
  • Gerburg M. Wulf

DOI
https://doi.org/10.1159/000529859
Journal volume & issue
Vol. 16, no. 1
pp. 811 – 817

Abstract

Read online

There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk. On the other end, for those diagnosed with breast cancer, there are no clinical guidelines to manage their breast cancer, specifically, how to manage their gender-affirming hormone therapy during breast cancer treatment. Here, we report a 52-year-old transman diagnosed with a grade 2 invasive ductal carcinoma (ER+/PR+/HER2−), and ductal carcinoma in situ (DCIS) of intermediate grade. We discussed his risk factors as well as treatment options.

Keywords